Tesamorelin — Research Overview

Introduction

Tesamorelin is a synthetic polypeptide composed of 44 amino acids analogous to growth hormone-releasing hormone (GHRH). Structural modifications at both the N-terminus and C-terminus are suggested to improve peptide stability and resistance to enzymatic breakdown [1]. Tesamorelin binds to GHRH receptors at the anterior pituitary, stimulating secretion of growth hormone (GH), which in turn induces insulin-like growth factor-1 (IGF-1) synthesis [1]. Through this mechanism, Tesamorelin is studied for its potential effects on fat metabolism, lipodystrophy, cognition, and muscle composition.

Chemical Characteristics

Other Known Titles: (3E)-hex-3-enoylsomatoliberin

Research Applications

1. Lipodystrophy

– Phase III trials in HIV-associated lipodystrophy demonstrated Tesamorelin reduced visceral adipose tissue by ~15% at 26 weeks, with improvements in triglyceride and cholesterol levels [6].

2. Liver Fat and NAFLD

– In HIV-positive patients with fatty liver, Tesamorelin reduced hepatic fat fraction in 35% of subjects compared to 4% on placebo over 12 months [5,7].

3. Cognition

– Clinical study of older HIV-positive adults with mild cognitive impairment evaluated Tesamorelin over 6–12 months; interim reports suggest possible improvement in Global Deficit Score (GDS) [8].

4. Insulin Sensitivity

– In type 2 diabetes subjects, Tesamorelin did not significantly alter fasting glucose, HbA1c, or insulin sensitivity indices over 12 weeks [9].

5. Muscle Tissue

– CT imaging studies suggested Tesamorelin increased muscle density and reduced intramuscular fat, particularly in rectus abdominis and paraspinal muscles [10].

6. Visceral Fat Reduction

– In lipodystrophy models, Tesamorelin reduced visceral fat by up to 25%, supporting its proposed role in metabolic regulation [11].

Conclusion

Tesamorelin is a stabilized 44-amino acid GHRH analog that retains the capacity to stimulate GH secretion and increase IGF-1. Its research applications include lipodystrophy, NAFLD, cognition, and muscle metabolism. While results are promising in targeted conditions, Tesamorelin is designated strictly for research use.

Tesamorelin — References

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Clinical and Research Information on Drug-Induced Liver Injury: Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2018.https://www.ncbi.nlm.nih.gov/books/NBK548730/
• Spooner, L. M., & Olin, J. L. Tesamorelin: a growth hormone–releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240–247.https://doi.org/10.1345/aph.1Q629
• Stanley, T. L., Chen, C. Y., Branch, K. L., Makimura, H., & Grinspoon, S. K. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology & Metabolism. 2011;96(1):150–158.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038486/
• Ferdinandi, E. S., Brazeau, P., High, K., Procter, B., Fennell, S., & Dubreuil, P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology. 2007;100(1):49–58.https://pubmed.ncbi.nlm.nih.gov/17214611/
• Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., & Grinspoon, S. K. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV. 2019;6(12):e821–e830.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981288/
• Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291–4304.https://pubmed.ncbi.nlm.nih.gov/20554713/
• ClinicalTrials.gov. Tesamorelin Effects on Liver Fat and Histology in HIV (NCT02196831).https://clinicaltrials.gov/ct2/show/NCT02196831
• ClinicalTrials.gov. Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons (NCT02572323).https://clinicaltrials.gov/ct2/show/NCT02572323
• Clemmons, D. R., Miller, S., & Mamputu, J. C. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS ONE. 2017;12(6):e0179538.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/
• Adrian, S., Scherzinger, A., Sanyal, A., Lake, J. E., Falutz, J., Dubé, M. P., Stanley, T., Grinspoon, S., Mamputu, J. C., Marsolais, C., Brown, T. T., Erlandson, K. M. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. Journal of Frailty & Aging. 2019;8(3):154–159.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766405/
• Sivakumar, T., Mechanic, O., Fehmie, D. A., & Paul, B. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Medicine. 2011;12(8):453–462.https://pubmed.ncbi.nlm.nih.gov/21265979/

NOTICE OF COMPLIANCE

The mission of BioGenix Peptides™ is to provide researchers with the highest-quality, Ultra-Pure Series™ compounds to help unlock the full potential of this evolving field. With precision, purity, and scientific integrity at the core of our operations, BioGenix Peptides™ is dedicated to supporting responsible exploration and discovery

Products from BioGenix Peptides™ are not intended for human consumption. They are supplied exclusively for in-vitro and pre-clinical research purposes.

By purchasing or using these products, the Customer accepts full responsibility for their handling and use, and agrees to indemnify and hold BioGenix Peptides™ harmless from any claims resulting from misuse.